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INTRODUCTION 34
Clinical risk-prediction models (CRPMs, also known as prognostic models or 35 risk score models) serve an important role in healthcare, 1 particularly for binary 36 adverse events (in-hospital, 30-day, or operative mortality) after cardiac, thoracic, 37 and vascular surgery. These models may be applied to 3 different objectives: 1) to 38 assess patient risk, which surgeons and patients can then factor in to healthcare 39 decisions; 2) to stratify risk, both for clinical decision-making and inclusion criteria in 40 a controlled randomized trial, 2 and 3) to assess and compare healthcare outcomes 41 among providers (benchmarking). The comparison of observed with expected 42 outcomes, accounting for statistical uncertainty, can identify underperforming 43
healthcare providers for quality improvement interventions. 3 44
The wide-ranging importance of CRPMs in the cardiovascular specialty 45 means that stakeholders must have confidence in them. A poorly performing model 46 can lead to suboptimal decision-making, misinformed patients, false reassurance of 47 a healthcare provider's performance, or false stigmatization of the provider. which evaluates the generalizability (or transportability) of the model to other groups 53 of patients, is fundamental to demonstrating a model is appropriate for adoption in 54 clinical practice. 4 In cardiovascular and thoracic surgery, the majority of CRPMs 55 encountered will predict binary outcomes, which were created using multivariable 56 regression techniques, in particular logistic regression. Therefore, we focus our 57 discussion to this area. However, the general principles and need for external 58 5 validation apply to other outcome types and models, e.g. time-to-event data, 5,6 as 59 well as to non-regression techniques, e.g. machine learning approaches. 7 60 61
MODEL PERFORMANCE CONCEPTS 62
Performance of CRPMs is typically based on assessing two important 63 features: calibration and discrimination. 6 64
Calibration is the accuracy of the model for predicting events relative to 65 observed events in groups of patients. For example, if the mean predicted event 66 occurrence is 5% in a patient group, but the observed event occurrence is 10%, then 67 we conclude the model is not well calibrated because it underpredicts. 68
Discrimination is the ability of a model to distinguish between patients who 69 experienced the event and those who did not. Discrimination is measured using the 70 area under the receiver-operating-characteristic curve (AUROC), also referred to as 71 the concordance (c-)statistic or c-index. 5 This value has a meaningful interpretation. 72
If we randomly select 2 patients, 1 who experienced the event and 1 who did not, 73 then the AUROC is equivalent to the probability that the risk score attributed to the 74 former is greater than that attributed to the latter. An AUROC of 1 indicates perfect 75 classification; a value of 0.5 is equivalent to tossing a fair coin. 76
Other aspects of performance assessment include clinical usefulness, 77 impact, 8 and overall performance measures such as the Brier score 9 and 78 concordance index, particularly for time-related events. 79
80

DESIGNING AND REPORTING AN EXTERNAL VALIDATION 81
When designing a validation study, thought must be given to several key 82 elements. 83 6 Selection of patients. The selection of patients used to externally validate a 84 CRPM might differ from those used to develop the model. These differences might 85 be temporal or geographical, or related to clinical setting, inclusion or exclusion 86 criteria, definitions, diagnostic techniques, or inherent baseline case-mix differences 87 between the two populations. It is important to highlight any differences that might 88 affect model transportability between the validation and original study sample, 89 particularly with validation of general all-surgery models (e.g. the EuroSCORE) 90 within procedural 10 or operative subgroups. 11 91 Risk factor data. It goes without saying that calculating a risk score requires 92 access to all variables that comprise the risk score. One potential issue is conflict in 93 variable definitions. For example, a registry that only collects binary data on whether 94 pulmonary artery (PA) systolic pressure is >60 mmHg (a risk factor in the logistic 95 EuroSCORE model) would not be able to compute the EuroSCORE II risk score, 96 which includes model coefficients for PA systolic pressures of 31 -55 mmHg and 97 >55 mmHg. This is primarily an issue for retrospective validation studies, as clinical 98 registries can be updated to capture contemporary risk-score data. 99
Missing data. One cannot calculate a risk score without access to data for 100 variables that comprise the CRPM. If a model contains a risk factor such as 101 preoperative serum creatinine, but these data are sparsely available in the dataset, 102 then in many cases the risk score cannot be calculated. Case-complete analyses-103 those that delete subjects with missing data for required variables-might lead to 104 bias if those subjects are not representative of the whole population. 12 In certain 105 cases, reasonable estimates and assumptions can be made based on clinical 106 expertise or additional information in the dataset. For example, a number of variables 107 in Society of Thoracic Surgeons (STS) risk models have coefficients set to 0 for 7 some variables in some models; if one is validating such a model, missing data for 109 such a variable is of no consequence. Alternatively, statistical imputation or subset 110 analysis techniques might be applied to compensate. 13, 14 If a validation study 111 specifically excludes certain groups of patients (for example, emergency surgery, 112 reoperations, or endocarditis), imputation of 0 is an accurate and appropriate 113 substitution, but the validation is only partial. In any case, it is always necessary to 114 summarize the frequency of missing data and present methods for managing it and 115 its assumptions. 116
Sample size. Considerations regarding sample size should not be limited to 117
randomized control trials. Single-center validation studies will often have a limited 118 pool of subjects, especially for subgroup analyses, and increasing the sample size 119 will require widening the study period, which could come at a price (see comment on 120 calibration drift below). When designing a study, sample size (number of subjects) 121 alone is not enough; one must also consider effective sample size (number of 122 events). Relatively little attention has been given to this matter, but some studies 123 have recommended a minimum of 100 events and 100 non-events for validation 124 studies, and in certain applications, larger effective sizes will be required to obtain 125 adequate power. 15 Large study windows. One simple way to increase sample size in a 144 validation study is to widen the study window. However, validation of a CRPM over a 145 substantially wide period can introduce a number of complexities. One potential 146 issue is calibration drift. 26, 27 Multiple studies demonstrated that the ratio of observed been improved with guidelines such as the CONSORT statement 28 for randomized 155 trials and the PRISMA statement 29 for systematic reviews and meta-analyses. 156
Prompted by evidence of poor quality reporting in the CRPM literature, the recent 157 TRIPOD statement describes reporting guidelines for studies developing, validating, 9 or updating a prediction model. 30 We strongly encourage researchers to follow these 159 guidelines and make use of the checklist for validating models. Examples of good 160 practice and additional details have been previously published. 31 to a test based on 10 groups composed by deciles of risk. However, authors should 172 be aware that there are variations on the test with regard to groupings (quantiles vs. 173 fixed cut-points), number of groups (g), degrees of freedom of the chi-squared 174 statistic (g-2 for internal vs. g for external validation), and software 175 implementations. 35, 36 While g is typically selected to be 10, one must ensure the cell 176 counts are sufficient to justify the distributional approximation. Including a table of 177 Further details are given in Harrell (2001) 38 and Harrell (2015) . 46 Code to reproduce 372 this plot is given in the Appendix. 373 374
